Skip to main content
Top
Published in:

Open Access 01-12-2025 | Toxoplasmosis | Research

T-cell activation of Toxoplasma gondii positive donors by maltodextrin nanoparticles formulated with killed Toxoplasma gondii

Authors: Monica Vargas-Montes, François Fasquelle, Nestor Ivan Cardona, Jorge Enrique Gómez-Marín, Didier Betbeder

Published in: BMC Infectious Diseases | Issue 1/2025

Login to get access

Abstract

Nasal vaccination with killed tachyzoites from Toxoplasma gondii loaded in lipidated maltodextrin nanoparticles (NPL/T.gondii) has been shown to induce protection against lethal T.gondii infection in mice, sheep and squirrel monkeys. This protection was related to a unique T-cell mediated response (Th1 and Th17). In immunocompetent humans T.gondii infection is generally asymptomatic but leads to the formation of cysts in several organs. These cysts may reactivate during episodes of immunosuppression, owing to a Th1 immune exhaustion, leading to numerous complications. The objectives of the current study were to assess whether NPL/T. gondii vaccine can stimulate a specific IFN-γ secretion on peripheral blood mononuclear cells (PBMC) of Toxo-positive donors, in order to potentially prevent reactivation of the parasite. By using enzyme-linked immunospot (ELISpot) assays, the frequency of IFN-γ producing cells was quantified after 72 h of stimulation. This stimulation was specific of the Toxo + donors’ memory T-cells. The uptake of this formulation by PBMCs was evaluated using flow cytometry, more particularly in T lymphocytes (CD3 + CD4 + and CD3 + CD8 +), B lymphocytes (CD3- CD19 +) and natural killer cells (CD3- CD56 +). Surprisingly, a lower antigen uptake was observed in all cell populations from Toxo + donors compared with the seronegative ones. Further in vitro analysis revealed that the early specific IFN-γ secretion by stimulated memory cells from Toxo-positive donors inhibited the endocytosis mechanism, therefore lowering their own vaccine uptake. These results suggest that NPL/T.gondii formulation can specifically trigger the existing Th1 immune response in positive donors, reinforcing their ability to control infection and reactivation.
Appendix
This content is only visible if you are logged in and have the appropriate permissions.
Literature
This content is only visible if you are logged in and have the appropriate permissions.
Metadata
Title
T-cell activation of Toxoplasma gondii positive donors by maltodextrin nanoparticles formulated with killed Toxoplasma gondii
Authors
Monica Vargas-Montes
François Fasquelle
Nestor Ivan Cardona
Jorge Enrique Gómez-Marín
Didier Betbeder
Publication date
01-12-2025
Publisher
BioMed Central
Keyword
Toxoplasmosis
Published in
BMC Infectious Diseases / Issue 1/2025
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-025-10656-5

Prof. Chantal Mathieu highlights how the absence of rigorous performance standards for continuous glucose monitors in Europe contributes to wide variability in device accuracy, raising important concerns about patient safety.

Supported by: Abbott Diabetes Care

Watch the full video

Prof. Chantal Mathieu highlights how the absence of rigorous performance standards for continuous glucose monitors in Europe contributes to wide variability in device accuracy, raising important concerns about patient safety.

Supported by: Abbott Diabetes Care

Log in / Register to watch the full video

Innovations in AML: insights and practical guidance

Hear directly from acute myeloid leukemia experts in this vodcast series focussing on innovations in molecular testing, emerging therapies, and targeted treatments, and get practical advice for improving the care of your patients with relapsed or refractory disease.

Supported by:
  • Rigel Pharmaceuticals, Inc.
Developed by: Springer Health+ IME
Learn more

ADA 2025: the 85th Scientific Sessions

Unlock your free and exclusive access to the latest news from the American Diabetes Association’s annual meeting.

Read more